tirzepatide dual agonist Tirzepatide, a GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction | Cardiovascular Diabetology led and built for women Comparison between GLP-1 RA and

Weight loss medications In addition to dietary and lifestyle modification, the use of weight loss medications should be considered for patients with weight regain after sleeve gastrectomy

MariTide Name: Maridebart cafraglutide (MariTide, formerly AMG 133) Manufacturer: Amgen Current stage: US phase III trial currently underway (MARITIME, NCT06858839) Takeaway: The dual agonist/antagonist action of MariTide could promise higher weight loss with fewer side effects, with dosing at less frequent intervals but more studies are needed

Navigating insurance can be confusing

J Pers Med

During the maintenance phase, well continue to be your partner in success